Hepatitis B vaccination induces mucosal antibody responses in the female genital tract, indicating potential mechanisms of protection against infection by Simpson, Samuel J. et al.
This is a repository copy of Hepatitis B vaccination induces mucosal antibody responses in
the female genital tract, indicating potential mechanisms of protection against infection.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/141212/
Version: Accepted Version
Article:
Simpson, Samuel J., Wiggins, Rebecca, Fox, James Martin 
orcid.org/0000-0002-2473-7029 et al. (3 more authors) (2018) Hepatitis B vaccination 
induces mucosal antibody responses in the female genital tract, indicating potential 
mechanisms of protection against infection. Sexually transmitted diseases. ISSN 
0148-5717 
https://doi.org/10.1097/OLQ.0000000000000949
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
ARTICLE COVERSHEET
LWW_CONDENSED(7.75X10.75)
SERVER-BASED
Article : OLQ50645
Creator : dpc_lww
Date : Tuesday December 11th 2018
Time : 10:48:58
Number of Pages (including this page) : 6
Hepatitis B Vaccination Induces Mucosal
Antibody Responses in the Female Genital Tract,
Indicating Potential Mechanisms of Protection
Against Infection
Samuel J.AQ1 Simpson, MBChB, BMedSci, Rebecca Wiggins, PhD, James M. Fox, PhD,
Jabu Mthethwa, FRCSEd, MBChB, Chun Cai, MBChB,
and Charles J.N. Lacey, MD, FRCP
Abstract: Vaccines against hepatitis B virus confer effective protection.
Enzyme-linked immunosorbent assay was developed to test for specific an-
tibodies in female genital tract secretions. Anti–hepatitis B IgG and IgA
were detected in the cervicovaginal secretions of women after hepatitis B
vaccination, indicating a potential genital tract role for neutralizing antibod-
ies against sexually transmitted hepatitis B virus.
Hepatitis B virus (HBV) is a prevalent blood-borne and sexu-ally transmitted pathogen. Current HBV prevention relies
on second-generation yeast-derived recombinant DNA vaccines
targeting the conserved immunodominant “a” region of the hep-
atitis B surface antigen (HBsAg) small protein. These vaccines
confer rapid protection in most recipients via neutralizing anti-
HBsAg antibody induction (anti-HBs)1 and long-lived cellular
memory responses.2Despite the success of these vaccines, concerns
remain regarding nonresponders, mother-to-child transmission, es-
cape mutants, and suboptimal vaccine antigenicity, highlighting
the need for ongoing HBV vaccine research.3
Hepatitis B immune globulin activity in postexposure and
posttransplant prophylaxis of HBV infection has led to the conven-
tion that the mechanism of action of HBVantibodies in preventing
infection is systemic.4 Little work has been performed investigat-
ing the potential role of neutralizing antibodies at mucosal levels
in relation to sexually transmitted HBV. Our aim was to investi-
gate the genital mucosal antibody response in women vaccinated
with Engerix-B (GSK, LondonAQ2 , United Kingdom), the most
widely used HBV vaccine in the United Kingdom. Evidence of
anti-HBs in cervicovaginal secretions could indicate that HBV
vaccine-induced responses may also be protective at the level of
the genital mucosa in the context of sexually transmitted HBV
infection.
MATERIALS AND METHODS
Healthy, asymptomatic women aged 18 to 45 years were
recruited from 2 sexual health clinics (York and Harrogate,
Yorkshire, United Kingdom) after gaining informed consent.
Serum was obtained from 17 volunteers (7 previously vacci-
nated intramuscularly, 10 unvaccinated). Of these, 5 vaccinated
and 7 unvaccinated women provided cervical and vaginal muco-
sal samples. Two further volunteers (1 vaccinated, 1 unvacci-
nated) provided mucosal samples, bringing the total mucosal
samples available to 6 vaccinated and 8 unvaccinated.
Endocervical and vaginal wall secretion sampling and stor-
age was undertaken as previously described5 using Weck-Cel sur-
gical spears (Medtronic, Minneapolis, MN); secretion dilution
factors were calculated according to Rohan et al.6 Calculations
for blood contamination in mucosal samples were undertaken based
on methods of Kozlowski et al.7 Mucosal samples were not ob-
tained during menstruation to reduce blood contamination. Serum
samples were centrifuged at room temperature for 10 minutes at
1500g; the serum portion was stored at −20°C.
Enzyme-Linked Immunosorbent Assays for
HBsAg-Specific IgG and IgA in Serum, and
Cervical and Vaginal Secretions
Indirect enzyme-linked immunosorbent assays (ELISAs)
for IgG and IgA anti-HBs were developed for sera and mucosal
samples by testing different experimental parameters: coating
(assay) buffer, pH, concentration of antigen, blocking buffer,
and sample concentration using checkerboard titrations with
samples of known HBV vaccination status. A serum sample
from an HBV-vaccinated individual with a known titer of total
anti-HBs antibody (Architect; Abbott Laboratories, Abbott Park,
IL) was used to create a 4-point standard curve and assigned units
per milliliter from which sample values could be interpolated.
Washing steps were undertaken using an automated plate washer
(Scanwasher 400; Cox Scientific, Northants, United Kingdom)
containing phosphate-buffered saline + 0.05% Tween 20 (PBST;
Sigma-Aldrich, Poole, United Kingdom).
The ELISA established after development was undertaken
as follows with all incubations at 37°C for 1 hour until substrate
addition: Greiner Bio-One 96-well medium-binding microplates
(Jencons, Leighton Buzzard, United Kingdom) were coated 1:1
with 50 μL of 10 μg/mL recombinant HBsAg (Engerix-B) in
0.1 M Na2CO3 and 0.1 M NaHCO3 (carbonate buffer) with assay
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buffer blanks and then incubated. Unbound material was washed
off with PBST, and plates were blocked with 10% fetal bovine se-
rum in PBST. Plates were washed and the sample was added in
triplicate. Samples were washed and peroxidase conjugate–linked
Fc-specific IgG and IgA was added (Sigma-Aldrich). Plates were
washed, and 3,3′5,5 tetramethylbenzidene substrate (KPL Inc,
Gaithersburg, MD) was added and incubated for 5 minutes at
room temperature; reaction was stopped by the addition of stop
solution (KPL Inc). Absorbance was measured immediately after
stop solution addition at 450 nm on a Bio-Rad 550 plate reader
(Bio-Rad, Watford, United Kingdom). Triplicate sample optical
densities (ODs) were averaged, and final OD was gained by
subtracting buffer blank OD. Units per milliliter of anti-HBs in
samples was interpolated from the standard curve and corrected
for dilution factors.
Datawere analyzed and plotted graphically (GraphPadPRISM
v7.0c; GraphPad Software Inc, La Jolla, CA). Comparisons in
antibody levels between groups were performed using the
Mann-Whitney U test. The relationship between serum and
mucosal HBsAg-specific IgA and IgG levels was analyzed using
the Spearman rank correlation coefficient.
RESULTS
Characteristics of the Study Cohorts
Vaccinated women were 26 to 42 years of age (median,
33 years), and unvaccinated women were 20 to 37 years of age
(median, 26 years). There were missing data in the recording
of contraceptive status, but of the 12 women, 4 were using com-
bined oral contraception, 3 were using progesterone only, 2 were
using the Mirena, and 3 were using barrier methods, with methods
recorded in both cohorts.
Concentrations of specific IgG and IgA anti-HBs detected
in serum, cervical, and vaginal samples are shown inF1 Figure 1.
ELISA for HBsAg-Specific Serum IgA and IgG
Hepatitis B surface antigen–specific serum IgG levels in
the vaccinated group (n = 7; median, 98.3 U/mL) were markedly
greater than those in the unvaccinated group (n = 10; median,
7.95 U/mL; P = 0.0002). The vaccinated group's HBsAg-specific
serum IgA levels (n = 7;median, 34.9U/mL)were also significantly
higher than those in the unvaccinated (n = 10; median, 9.8 U/mL;
P = 0.043), but with a smaller disparity.
ELISA for HBsAg-Specific Mucosal IgA/IgG
Hepatitis B surface antigen–specific cervical IgG levels in
the vaccinated group (n = 5; median, 18.4 U/mL)were greater than
those in the unvaccinated (n = 7; median, 1.30 U/mL; P = 0.0025).
The vaccinated group's HBsAg-specific cervical IgA levels (n = 6;
median 6.33 U/mL) were also greater than those in the unvacci-
nated (n = 8; median, 1.75 U/mL; P = 0.008). There was no statis-
tically significant difference in HBsAg-specific vaginal IgG in
vaccinated (n = 5; median, 3.78 U/mL) compared with the un-
vaccinated (n = 8; median, 1.52 U/mL; P = 0.09), although
HBsAg-specific vaginal IgA in vaccinated (n = 5; median,
7.39 U/mL) were greater than the unvaccinated (n = 8; median,
1.48 U/mL; P = 0.006).
Correlation Between HBsAg-Specific Serum and
Mucosal IgA and IgG
A statistically significant correlation existed between serum
and cervical anti-HBsAg IgG (P = 0.033), with cervical levels be-
ing 20.8% (95% confidence interval, 12.6%–40.4%) of those in
serum. There was a nonsignificant correlative trend (P = 0.06) be-
tween serum and vaginal anti-HBsAg IgA, with vaginal levels be-
ing 6.6% (95% confidence interval, 0.9%–12.3%) of those
recorded in serum. Cervical IgA and vaginal IgG were not signif-
icantly correlated with serum.
DISCUSSION
A novel ELISAwas developed to test for HBsAg-specific
IgG and IgA in female genital tract mucosal secretions. We found
that anti-HBs IgG and IgA can be detected in the cervicovaginal
secretions of women after intramuscular Engerix-B vaccination.
Anti-HBs levels were greater in serum than in mucosal samples,
and IgG levels were greater in cervical than vaginal samples.
Our study was limited by sample size, sample volumes, in-
complete sample sets, and no definitive data for the participants'
exact vaccination dates. We included extra samples in addition to
the 12 matched pairs to demonstrate assay performancewith every
available sample in this small study. All correlations were per-
formed on matched pairs only. We also consequently focused on
measuring specific rather than type-specific anti-HBs. We con-
sider this a reasonable approach because the women were on vary-
ing contraceptive methods and only 3 of 12 women for whom we
have contraceptive data could be said to have had normal men-
strual cycle, during which antibody levels will fluctuate.
Our data are comparable to that of Nardelli-Haefliger et al.,8
who investigated the presence of antibodies against human papil-
lomavirus (HPV) virus-like particles in cervical secretions in
women vaccinated with an HPV virus-like particle vaccine. As
they did, we showed a significant titer of vaccine-induced IgG an-
tibodies in cervical secretions. Because of our smaller study, we
could not show the cyclical variation in antibody levels in women
with ovulatory cycles they demonstrated, but like them, we did ob-
serve a significant relationship between systemic and cervical spe-
cific IgG levels with a similar ratio, supporting transudation as the
primary source of genital tract IgG.8–10 The data also suggested a
possible correlation between systemic and vaginal IgA anti-
HBsAg. This is less well understood but could be due to a combi-
nation of factors including transudation from the systemic circula-
tion9 as well as local production11 perhaps associated with plasma
cell trafficking.10
The significance of secreted anti-HBs in the female genital
tract is currently unknown. However, ~80% of hepatitis B vaccine–
induced neutralizing antibodies are IgG1 subclass, AQ31 and 90% of
cervicovaginal IgG antibodies are also IgG1 subclass.9 In contrast
to other mucosal surfaces, IgG is the dominant isoform in the cer-
vix as opposed to IgA.12 The mechanism of action of neutralizing
antibodies in the female genital tract is well described in the con-
text of HPV vaccination.13 However, HPV is a purely epithelial
pathogen with its target cells present in the anogenital mucosae,
whereas HBV needs to undergo systemic dissemination to reach
its target cells, including those in the liver. Hepatitis B virus infects
a wide range of cell types in both acute and chronic infection, in-
cluding lymphocytes, monocyte/macrophages, and neutrophils.14,15
All these migratory hemopoietic cells express HSPGs, which act as
an HBV receptor.16 Overall, it seems likely that peripheral blood
mononuclear cells ferry HBV from the anogenital tract to the
liver, as they are a known transmission mechanism for mother-
to-infant infection.17
We suggest that our data support a hypothesis that vaccine-
induced anti-HBs antibodies, both secreted in the genital tract and
systemic, act in concert with innate immune mechanisms to neu-
tralize HBV, both at the portal of entry and on any migratory cells
or in distal tissues before the HBV virion is able to mature18 and
successfully transit to its primary target, the hepatocyte. A larger
study could explore these proposed mechanisms.
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Figure 1. Concentration of anti-HBs in serum, cervical, and vaginal secretions. Enzyme-linked immunosorbent assays were performed to
detect anti-HBs in the serum of control (n = 10) or vaccinated (n = 7) and cervical and vaginal secretions of control (n = 8*) or vaccinated
(cervical, n = 6*; vaginal, n = 5) women. Data of individual participant are plotted as a separate matched color in the respective control (square
symbols) or vaccinated (circular symbols) groups, with median detected concentration shown as the major horizontal line. Error bars show
interquartile range. Statistical comparisons between data sets are indicated with corresponding P values. *One sample had insufficient volume
available for all mucosal assays.
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